Central Valley Advisors LLC Raises Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Central Valley Advisors LLC grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 13.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 17,639 shares of the medical research company’s stock after buying an additional 2,145 shares during the quarter. Central Valley Advisors LLC’s holdings in Edwards Lifesciences were worth $1,306,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in EW. J.W. Cole Advisors Inc. boosted its holdings in Edwards Lifesciences by 7.4% in the second quarter. J.W. Cole Advisors Inc. now owns 2,956 shares of the medical research company’s stock worth $273,000 after purchasing an additional 204 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Edwards Lifesciences by 18.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,399,329 shares of the medical research company’s stock valued at $129,271,000 after buying an additional 219,486 shares during the period. Edgestream Partners L.P. purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth $438,000. Bradley Foster & Sargent Inc. CT grew its holdings in shares of Edwards Lifesciences by 17.9% in the second quarter. Bradley Foster & Sargent Inc. CT now owns 16,842 shares of the medical research company’s stock worth $1,556,000 after acquiring an additional 2,563 shares during the period. Finally, Meiji Yasuda Asset Management Co Ltd. increased its position in Edwards Lifesciences by 1.2% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company’s stock valued at $1,417,000 after acquiring an additional 184 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Down 0.6 %

Shares of EW stock opened at $69.87 on Friday. The company’s fifty day simple moving average is $71.91 and its two-hundred day simple moving average is $71.61. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a market cap of $41.21 billion, a P/E ratio of 10.08, a PEG ratio of 3.77 and a beta of 1.11. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.59 earnings per share. Analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock valued at $2,195,180 over the last 90 days. 1.27% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on EW shares. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Stifel Nicolaus boosted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Robert W. Baird reduced their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.